For BC patients (e.g., luminal A/B, triple-negative), the molecular subtype is typically determined by testing a tissue biopsy for the presence or absence of three essential proteins: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)45. This evidence concerns the gene ESR1 and breast cancer.